Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy side effects under the microscope: new study monitors autoantibodies

NCT ID NCT04220034

Knowledge-focused Sponsor: CHU de Reims Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies linked to autoimmune diseases. The goal was to better understand and potentially predict autoimmune side effects from these powerful cancer drugs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors predict and manage autoimmune side effects in cancer patients receiving checkpoint inhibitors.
What could go wrong
This is an observational study, not a treatment trial. It only measures antibody levels and does not test any new therapy or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

183 people

The number who actually took part.

Started

Jan 2020

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients receiving inhibitor checkpoint treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients receiving check point inhibitor for a neoplasic disease in a center that participates to the study during the inclusion period * patients who agree to participate in the study * adult patients (aged more than 18 years old) Exclusion Criteria: \- previous treatment with check point inhibitor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune adverse effects of anti-neoplasic drug are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplastic disease or syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune adverse effects of anti-neoplasic drug

Contacts and locations

Locations

  • Chu Reims

    Reims, 51092, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.